Hot Life Science Investor Mandate 3: Large Chinese VC Fund Seeking Early Stage Cross Border Life Science Investments

6 Aug

A venture capital firm based in Hong Kong has approximately USD 1 billion AUM and has raised 3 funds to date. The firm’s third fund was closed at USD 100 million in 2014. The firm makes early stage investments, typically in series A and B at USD 2-10 million, in the TMT and healthcare sector. The firm’s primary geographic focus is China and Asia, with a growing interest in cross-border opportunities in the US and EU.

In healthcare, the firm is interested in healthcare services, medical devices, early stage therapeutics, and specialty pharma. Within medical devices, the firm seeks growth stage products from MRI to IVD. Within therapeutics, the firm considers both small molecules and biologics. The firm is opportunistic in terms of subsectors and indications. The firm is interested in post-angel stage companies with products that are in pre-clinical or early clinical trials. Later stage opportunities can also be considered.

The firm seeks a strong and experienced management team and could act as lead investor or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: